Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PYRIDOSTIGMINE BROMIDE

All products: general benefit

Other products in the same Health Canada class (N07A) — coverage varies; not interchangeable

  • Bethanechol chloride (Duvoid): general benefit
  • Pilocarpine (Salagen): not a benefit

Mestinon · DIN 00869961 · 60mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mestinon · DIN 00869961 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2019-07-04 · brand MESTINON · ATC N07AA02 PYRIDOSTIGMINE · form Tablet · route Oral · ingredients PYRIDOSTIGMINE BROMIDE 60 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2673 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10567 · Verify on the e-Formulary ↗ (DIN 00869961)

Source record
DIN 00869961: Mestinon Raw flags: sec3=Y Item: 120400010; group id 196; item number 0361; lccId None; manufacturer id VAL Source form: Tab; strength: 60mg Recorded listing: General benefit Source prices (unrounded): $0.6512; ministry $0.2673 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00869961 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10567
Interchangeable products
Jamp Pyridostigmine Bromide · DIN 02508362 · $0.2673 Riva-Pyridostigmine · DIN 02495643 · $0.2673
Shortage status: resolved shortage (ended 2024-03-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00869961
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (12:04 Parasympathomimetic (Cholinergic) Agents) and how they are covered

Matched class: 12:04 Parasympathomimetic (Cholinergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETHANECHOL CHLORIDE, CARBACHOL 12:04 Parasympathomimetic (Cholinergic) Agents

BETHANECHOL CHLORIDE

· 3 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

PILOCARPINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg · Tab

CARBACHOL

· 1 products · General benefit · strengths: 2mg · Tab

DONEPEZIL HCL

· 48 products · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 347, 348 (42) · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

GALANTAMINE HYDROBROMIDE

· 18 products · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) · strengths: 8mg, 16mg, 24mg · ER Cap

RIVASTIGMINE

· 34 products · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.5mg, 3mg, 4.5mg, 6mg, 9mg/5 Sq Cm, 18mg/10 Sq Cm · Cap, Trans Patch Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:04
Full class listing Related classes: 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS MESTINON and MESTINON-SR are indicated for the symptomatic treatment of myasthenia gravis. In acute myasthenic crises where difficulty in breathing and swallowing is present, the parenteral form should be used. The patient can be transferred to the oral form as soon as it can be tolerated. https://pdf.hres.ca/dpd_pm/00052033.PDF PM date: July 3, 2019 Source product: MESTINON-SR; DIN 00869953; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.